G. D'Haens

Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study (2007)

Louis, Edouard, Boverie, Jacques, Dewit, O, Baert, F, De Vos, M, D'Haens, G

Stricturing subocclusive small bowel Crohn's disease (CD) is often an indication for surgery. We embarked on an open label pilot study to assess the safety and efficacy of infliximab in patients with...

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease (2006)

Mikhajlova, T L, Stoinov, S, Stimac, D, Vucelic, B, Lonovics, J, ...

INTRODUCTION: Interferon gamma is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised...

Myenteric ganglionitis in unaffected ileal section margins predicts severe and early postoperative Crohn's disease recurrence (2005)

Hlavaty, T, D'Haens, G, Rutgeerts, Paul; U0007636, ...

The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study (2004)

D'Haens, G, Noman, M, ...

BACKGROUND: By temporarily suppressing the immune response, the anti-tumour necrosis factor agent, infliximab, may increase the risk of peri-operative complications. AIM: To test this hypothesis for...

A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis (2003)

Vogelsang, H, Ludwiczek, O, Lochs, H, Kaser, A, Colombel, J-F, ...

BACKGROUND: Pilot studies of interferon alpha (IFN-alpha) suggest a high remission rate in the treatment of active ulcerative colitis. We evaluated the safety of pegylated interferon alpha (PegIFN)...

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease (2002)

Vermeire, S, Louis, Edouard, Carbonez, A, Van Assche, G, Noman, M, Belaiche, Jacques, ...

OBJECTIVE: Infliximab is an effective treatment for refractory or fistulizing Crohn's disease (CD). However, about 30% of patients do not respond to infliximab for unknown reasons. Identifying...

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism (2002)

De Vos, M, Pescatore, P, ...

BACKGROUND: Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease respond to infliximab treatment. The ability or inability to respond seems to persist...

A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism (2002)

Louis, Edouard, Vermeire, S, Rutgeerts, P, De Vos, M, Van Gossum, A, Pescatore, Pierre, ...

Background: Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease respond to infliximab treatment. The ability or inability to respond seems to persist...

Ornidazol for prophylaxis of postoperative Crohn's disease: final results of a double blind placebo controlled trial (2002)

D'Haens, G, Noman, M, Aerden, I, ...

Budesonide in Collagenous colitis: A Double-Blind Placebo-Controlled Trial With Histologic Follow-Up (2002)

Baert, F., Schmit, A., D'Haens, G., Dedeurwaerdere, F., Louis, Edouard, Cabooter, M., ...

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis (2001)

D'Haens, G, Lemmens, L, Geboes, K, Vandeputte, L, Van Acker, F, ...

BACKGROUND & AIMS: Cyclosporine has been effective in patients with steroid-refractory attacks of ulcerative colitis (UC). We investigated the effects of intravenous (IV) cyclosporine as single IV...

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease (1999)

D'Haens, G, Targan, S, Vasiliauskas, E, Hanauer, S B, Present, D H, ...

BACKGROUND & AIMS: Infliximab, an anti-tumor necrosis factor monoclonal antibody, rapidly reduces signs and symptoms of active Crohn's disease. The aim of this study was to determine whether repeated...

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis (1999)

Baert, Frank; U0004588, Wouters, K, D'Haens, G, Hoang, P, Naegels, S, D'Heygere, F, ...

BACKGROUND AND AIMS: It is not known whether lymphocytic colitis and collagenous colitis represent different clinical entities or constitute part of a spectrum of disease. METHODS: Detailed clinical...

Nitroimidazol antibiotics are efficacious for prophylaxis of postoperative recurrence of Crohn's disease: a placebo controlled trial (1999)

D'Haens, G, Sels, F, Aerden, I, ...

Expression of gelatinase B in early recurrent Crohn's disease (1997)

Geboes, K, Paemen, L, D'Haens, G, Peeters, M, ...